Johnson & Johnson JNJ
Healthcare · Drug Manufacturers - General · United States · S&P 500
Based on the available data, Johnson & Johnson gets an algorithmic score of 62/100. It trades at 267.57 $, with a bullish technical trend (RSI 49.0) and 19.0% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (25.7%): generates strong profit on equity.
- High net margin (21.5%): pricing power / competitive advantage.
- Low beta (0.01): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 31.04 |
| Forward P/E | 22.04 |
| PEG | 2.82 |
| P/B | 7.58 |
| EV/EBITDA | 19.30 |
| P/S | 6.58 |
| ROE % | 25.74 |
| ROA % | 8.60 |
| Gross margin % | 68.14 |
| Operating margin % | 29.19 |
| Net margin % | 21.48 |
| Revenue growth % (y/y) | 6.60 |
| Earnings growth % (y/y) | -0.90 |
| Revenue CAGR % | 5.60 |
| Earnings CAGR % | 14.32 |
| Debt/Equity % | 57.71 |
| Current ratio | 1.09 |
| FCF yield % | 3.00 |
| Dividend yield % | 2.00 |
| Payout % | 60.79 |
Returns
| 1 month | -0.2 % |
| 3 months | +5.9 % |
| 6 months | +11.5 % |
| YTD | +31.1 % |
| 1 year | +52.2 % |
| 3 years | +81.5 % |
| 5 years | +87.0 % |
Risk
| 1-year volatility | 19.0 % |
| Beta | 0.01 |
| 5-year max drawdown | -18.4 % |
| Sharpe 1A | 2.10 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.